Belzutifan for advanced or metastatic clear cell renal cell carcinoma after 1 therapy

Belzutifan is currently in clinical development for the treatment of adult patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) after previous treatment. ccRCC is the most common type of kidney cancer and is called as such because the cancer cells appear clear when viewed under a microscope. Most patients with renal cell carcinomas (RCC) are usually asymptomatic in the early stage, but symptoms appear as the cancer progresses, which includes blood in the urine, anaemia (not enough healthy red blood cells), flank pain, weight loss and fatigue. Locally advanced cancer is when the cancer has grown outside the body part it started, whereas metastatic cancers have spread to other parts of the body. Treatment options for RCC in the late-line setting after previous treatments are limited.